Clinical trial NATALEE
A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE)
(CLEE011O12301C (TRIO033))
(CLEE011O12301C (TRIO033))
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Novartis |
| EudraCT Identifier | 2018-002998-21 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03701334 |
| Inclusion criteria | ER+/HER2-. Adjuvant. Pre or post menopausal |
| Last update |